
2012 represents a period with robust news flow for emerging immuno-oncology companies
February 5, 2012
MD Becker Partners' newsletter covering the life science industry

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

As the only company to receive a positive United States Food and Drug Administration [FDA] Advisory Committee [AdCom] recommendation for a product candidate to treat obesity in 2010, Orexigen Therapeutics, Inc. (OREX) appeared well positioned to receive marketing approval for Contrave® [naltrexone HCl/bupropion HCI]. However, on January 31, 2011, Orexigen and its partner Takeda Pharmaceutical [...]
Keynote address "Creating the methodological framework for cancer immunotherapy success" from MD Becker Partners' 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference:
Life Science Digest is published by MD Becker Partners LLC, a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry, including pharmaceuticals, biotechnology, and medical devices.
Interested in contributing articles to Life Science Digest? Send your request and a writing sample to: info@mdbpartners.com
Copyright © 2012 MD Becker Partners LLC · WordPress · Log in
Follow MD Becker Partners